Sensorion announces oral presentation at the European Histamine Research Society

Presentation of an overview of SENS-111 development

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage
biopharmaceutical company which specializes in the development of novel
therapies to restore, treat and prevent inner ear diseases such as
hearing loss, tinnitus and vertigo, will present a keynote plenary
lecture at the European Histamine Research Society in Kraków, Poland
from May 15-18th, 2019.

Contrary to typically sedative H1 receptor antagonist antihistamines
used in the management of vertigo, Seliforant (SENS-111) is a novel
first-in-class H4 receptor antagonist.

Sensorion will cover the translational development of Seliforant
starting from results of in vitro and in vivo preclinical models up
until the current proof-of-concept, clinical trial stage ongoing in AUV
patients (phase 2). This will include consistency between
pharmacokinetic/pharmacodynamic (PK/PD) relationships predicted from
preclinical models of severe vertigo and local target exposure
assessment in a phase 1b clinical trial, as well as confirmed lack of
sedation in the both the preclinical and clinical phase 2 setting.

The details of the oral presentation are as follows:
Session:
VII Scientific Session–Biologically active compounds
Title:
Translational development of Seliforant for the treatment of vertigo
Date
& Time: Friday, May 17^th from 12:15 PM – 12:45 PM CEST
Location:
International Cultural Centre Rynek Główny 25, 31-008 Kraków

About Seliforant
Seliforant (formerly SENS-111) is the first
representative candidate of the histamine type 4 receptor antagonist
class to be tested for the symptomatic treatment of vertigo crises.
Displaying a neuromodulation effect of the sensorineural inner ear cell
function, Seliforant is a small molecule that can be taken orally or via
a standard injection, and is currently in a separate Phase 2 clinical
trial, being conducted in the United States, Europe, Israel and South
Korea.

About Sensorion
Sensorion is a pioneering clinical-stage
biopharmaceutical company, which specializes in the development of novel
therapies to restore, treat and prevent inner ear diseases such as
hearing loss, vertigo and tinnitus. Our clinical-stage portfolio
includes two phase 2 products: Seliforant (SENS-111) in acute unilateral
vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural
hearing loss (SSNHL). We have built a unique R&D technology platform to
expand our understanding of the pathophysiology and etiology of inner
ear diseases enabling us to select the best targets and modalities for
drug candidates. We also identify biomarkers to improve diagnosis and
treatment of these underserved illnesses.

We are uniquely placed through our platforms and pipeline of potential
therapeutics to make a lasting positive impact on hundreds of thousands
of people with inner ear related disorders; a significant global unmet
need in medicine today.
www.sensorion-pharma.com

Disclaimer

This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking statements
are based on assumptions that Sensorion considers to be reasonable.
However, there can be no assurance that such forward-looking statements
will be verified, which statements are subject to numerous risks,
including the risks set forth in the ‘Document de référence’
registration document filed with the ‘Autorité des Marchés Financiers’
(AMF French Financial Market Authority) on September 7th, 2017 under
n°R.17-062 and to the development of economic conditions, financial
markets and the markets in which Sensorion operates. The forward-looking
statements contained in this press release are also subject to risks not
yet known to Sensorion or not currently considered material by
Sensorion. The occurrence of all or part of such risks could cause
actual results, financial conditions, performance or achievements of
Sensorion to be materially different from such forward-looking
statements.

This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of an
offer to purchase or subscribe for, Sensorion shares in any country. The
communication of this press release in certain countries may constitute
a violation of local laws and regulations. Any recipient of this press
release must inform oneself of any such local restrictions and comply
therewith.

Contacts

Sensorion
Nawal Ouzren
CEO
[email protected]
Tel:
+33 467 207 730

Catherine Leveau
Financial communication
[email protected]
Tel:
+33 467 207 730